Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

LUNG CANCER

Adjuvant TKIs — a long-term matter

Nature Reviews Clinical Oncology volume 16, page 67 (2019)Cite this article

Subjects

Access through your institution
Buy or subscribe

Disease relapse is common in patients with non-small-cell lung cancer (NSCLC) after surgery, highlighting the need for treatment optimization in the adjuvant setting. Now, the results of the SELECT trial demonstrate the potential of adjuvant erlotinib, an EGFR tyrosine-kinase inhibitor (TKI), in patients with EGFR-mutated NSCLC.

In this study, 100 patients with resected stage IA–IIIA EGFR-mutant disease received erlotinib for a median duration of 23 months. 2-year disease-free survival (DFS), the primary end point, was 88% (95% CI 80–93%), a value significantly higher than that of a historical control group of untreated patients (76%; P = 0.0047). 5-year DFS was 56%, and 5-year overall survival was 86%.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    Diana Romero

Authors
  1. Diana Romero
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Diana Romero.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romero, D. Adjuvant TKIs — a long-term matter. Nat Rev Clin Oncol 16, 67 (2019). https://doi.org/10.1038/s41571-018-0144-6

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41571-018-0144-6

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing